30 results about "S-methylcysteine" patented technology

A pharmaceutical with an enhanced pharmaceutical profile comprises a mucolytic and an antibiotic in which the mucolytic is present in an amount of greater than one molar equivalent of the antibiotic. The antibiotic may be selected from Erythromycin, Roxithromycin, Clarithromycin, Azithromycin, Dirithromycin; and pharmaceutically acceptable salts or esters thereof. The mucolytic is a mucolytically active thiol, especially N-acetylcysteine, mercaptoethanesulfonic acid, tiopronin or methylcysteine. The adducts can be isolated via a simple and efficient process.

The present invention relates to the fermentation process of producing L-arginine. By using Corynebacterium crenatum SYA5 screened and preserved by the present lab as parent and through conventional physical and chemical mutation process and multiple structural analog resistance screening, mutant strain SDNN403 is obtained. Through culturing of the mutant strain under optimized condition, L-arginine is produced in the yield level of 30-35 g / L. The strain has high genetic stability, stable yield characteristic, high L-arginine yield level, less produced hetero acids and easy technological amplification, and is suitable four industrial production.

The invention discloses a preparation method of chirality 2-methyl cysteine and hydrochloride thereof. The preparation method comprises the following steps: chirality 2-tert-butyl-3-formoxyl thiaxolidine-4-carboxylic ester, a methylation reagent and organic base are subjected to methylation in organic solvent to obtain reaction solution, inorganic base is added in the reaction solution, chirality-invariable 2-tert-butyl-3-formoxyl thiaxolidine-4-methyl-4-carboxylic acid is obtained through one-pot reaction, then the chirality-invariable 2-tert-butyl-3-formoxyl thiaxolidine-4-methyl-4-carboxylic acid is subjected to reflux reaction in hydrochloric acid solution to obtain chirality 2-methyl cysteine hydrochloride, and finally, chirality 2-methyl cysteine is obtained through aftertreatment. Compared with the prior art, the preparation method disclosed by the invention is simple in operating process, the production cost is lower, the reaction yield and the optical purity of products are higher, and excellent industrial application value is realized.

The present invention provides a simple industrial process for producing an L- or D-optically active α-methylcysteine derivative or its salt, which is a useful pharmaceutical intermediate, from readily available, inexpensive raw materials. In a process for producing an L- or D-optically active α-methylcysteine derivative or its salt, a racemic N-carbamoyl-α-methylcysteine derivative or its salt is D-selectively cyclized with hydantoinase to produce a D-5-methyl-5-thiomethylhydantoin derivative or its salt and an N-carbamoyl-α-methyl-L-cysteine derivative or its salt, which are then subjected to deprotection of the amino group and the sulfur atom, and hydrolysis.

The invention provides an S-carboxymethyl-L-cysteine ​​inclusion compound. The S-(carboxymethyl)-L-cysteine ​​clathrate of the present invention has a good dispersion effect, can effectively reduce the stimulation of S-(carboxymethyl)-L-cysteine ​​to the digestive tract, and increase the and the stability of its formulations. The enteric-coated preparation containing the clathrate can avoid being destroyed in the acidic environment of the stomach and reduce the irritation to the stomach; it directly reaches the small intestine at the absorption site, dissolves rapidly and releases the active ingredient, increasing the S-carboxymethyl-L- Bioavailability of cysteine.

The invention discloses an antimicrobial peptide Lexapeptide, and a preparation method and application thereof. The lanthiopeptin antimicrobial peptide Lexapeptide is a new compound obtained through separating after heterologously expressing a bacterial artificial chromosome library derived from a Streptomyces rochei Sal35 bacterial strain in Streptomyces lividans SBT5, is formed by 38 amino acids, and is the lanthiopeptin which is reported for the first time and simultaneously contains a C terminal 2-amidogen alkenyl-3-methyl-aminothiopropionic acid structure and an N terminal methylated modification structure. With the highly structural modification, the Lexapeptide has better stability compared with other lanthiopeptin antimicrobial peptides. The Lexapeptide can be used as an anti-gram-positive bacterium preparation so as to provide a solution for a generally clinical dug-resistance problem.

The invention discloses an S-(carboxymethyl)-L-cysteine ammonium anhydrous crystal form, and a preparation method and applications thereof. The X-powder diffraction pattern of the crystal form is represented by a pattern shown in the description. The preparation method of the crystal form is mild in reaction condition, simple in process and suitable for industrial production. The invention also discloses an application of the crystal form in the preparation of a phlegm eliminating medicine and an application of the crystal form in the preparation of a medicine for preventing and / or treating respiratory system diseases.

The invention discloses a drug or functional food for preventing or / and treating post-traumatic stress syndrome, which is composed of S-methyl-L-cysteine ​​(thiomethyl L-cysteine) or Amino acid salt of thiomethyl L-cysteine ​​and pharmaceutically or food industry-acceptable additives or / and carriers, described S-methyl-L-cysteine ​​can be composed of rich Provided by plant extracts containing S‑Methyl‑L‑Cysteine. The medicine or functional food of the present invention can reduce the level of oxidative stress in the body, reduce free radicals, enhance the synaptic plasticity of relevant brain regions dependent on NMDA receptors, etc., and produce the effect of promoting the dissipation of fear memory related to trauma stress, thereby treating trauma Behavioral abnormalities brought on by post-stress.

The invention discloses an S-carboxymethyl-L-cysteine enteric pellet. The enteric pellet contains a pellet core, an isolation layer and an enteric layer, wherein the enteric layer is obtained by coating and packaging a water-based acrylic acid enteric-coated material. The invention further discloses an S-carboxymethyl-L-cysteine enteric pellet capsule containing the S-carboxymethyl-L-cysteine enteric pellets. The S-carboxymethyl-L-cysteine enteric pellet capsule disclosed by the invention cannot be dissolved in the stomach, has a little stimulation to the stomach, and is stable in quality in astorage process.

The invention relates to a strain capable of producing L-arginine and a method for producing the L-arginine by the strain and belongs to the technical field of biological engineering. For the strain, Brevibacterium flavum ATCC 14067 is used as a starting strain; nitrosoguanidine is adopted to carry out mutagenesis step by step; mutant strains with histidine and succinic acid auxotrophic strains are screened out so as to cut off a competitive metabolic pathway; and mutant strains (His-, Suc-, D-Argr, SMCr) with resistances of arginine structural analogs and cysteine structural analogs are screened out. The strain is named as Brevibacterium flavum HX1009, is preserved in the China general microbiological culture collection center, has the preservation number of CGMCC No.4464 and has the genetic characters of histidine auxotroph His-, succinic acid auxotroph Suc-, D-arginine resistance D-Argr and S-methyl cysteine resistance SMCr for improving the yield of the L-arginine. Under the optimized condition, the L-arginine is produced by fermentation on a fermentation tank with the volume of 5L to 5M3 and the arginine production level achieves 50 to 70g / L.

The invention belongs to the technical field of compound preparation and particularly relates to a preparation method of high-purity S-(carboxymethyl)-cysteine. First, L-cysteine hydrochloride is pretreated by a reducing agent before reaction, an aqueous solution of chloroacetic acid is added into the system, and the reaction is continuously carried out in the positive reaction direction with dropping addition of an alkaline solution until the reaction is finished when the pH value of the system is 6.0-12.0, an acid is dropwise added to the vicinity of an isoelectric point of the product, andcrystallization is carried out at low temperature to obtain a crude product; the crude product is dissolved in the alkaline solution at room temperature, an organic acid is dropwise added until a product precipitates when the pH value is about 2.8, the precipitated product is put into a tray, the tray is put on the water surface and is pretreated by heating, moisture in a filter cake is heated until small bubbles are generated in the pretreatment process, and the generated bubbles counter-react with the filter cake, so that substances in the moisture in the filter cake further generate a precipitated product through the vibration effect of the bubbles, and finally the pretreated precipitated product is put into an all-in-one machine to obtain the product.

There is a significant demand for organic nitriles, based on their versatility in reactions. Compounds prepared from nitriles have properties including superoxide inhibition, ferrielectric liquid crystal dopant, antipicornaviral agents, anti-inflammatory agents, anti-asthma agents, and fibringoen antagonists. The present invention discloses a facile synthesis for 2,4-dihydroxybenzonitrile, and ethers and diethers thereof, from 2,4-dihydroxybenzoic acid. The present invention also discloses a method of preparing a class of iron chelating agents related to desferrithiocin, all of which contain a thiazoline ring. In this method, 2,4-dihydroxybenzonitrile is condensed with (S)-2-methylcysteine.

The invention provides an S-carboxymethyl-L-cysteine containing medicinal composition. The medicinal composition is an enteric tablet comprising a tablet core, an isolating layer and an enteric coating layer. The S-carboxymethyl-L-cysteine containing enteric tablet provided by the invention cannot be dissolved in the stomach and is low irritation to the stomach; the S-carboxymethyl-L-cysteine containing enteric tablet is dissolved in the small intestine as a main medicine absorbing site, improves the bioavailability of S-carboxymethyl-L-cysteine and is stable in quality during storage.